NCT01250197

Formulation Comparison in Normal Volunteers

A Double-masked, Crossover Study Assessing the Ocular and Systemic Safety and Systemic Absorption of Two Formulations of 0.5% AR-12286 Ophthalmic Solution in Normal Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 18 (estimated)
• Sponsor: Aerie Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

This is a double-masked, single-center, crossover study in which normal volunteers will be randomized to receive one of two formulations of 0.5% AR-12286 Ophthalmic Solution for 8 days. Subjects will undergo a minimum 7-day washout, and then receive the alternate treatment for 8 days.

Detailed description

Not desired.

Conditions

• Normal Volunteers

Interventions

Type	Name	Description
DRUG	AR-12286	Ophthalmic Solution

Timeline

• Start date: 2010-11-01
• Primary completion: 2010-12-01
• Completion: 2010-12-01
• First posted: 2010-11-30
• Last updated: 2010-12-22

Locations

1 site across 1 country: United States